Azmi Nabulsi Sells 7,886 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Stock

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) COO Azmi Nabulsi sold 7,886 shares of Phathom Pharmaceuticals stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $6.59, for a total value of $51,968.74. Following the completion of the transaction, the chief operating officer now owns 233,390 shares of the company’s stock, valued at approximately $1,538,040.10. This trade represents a 3.27 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Azmi Nabulsi also recently made the following trade(s):

• On Thursday, December 19th, Azmi Nabulsi sold 1,118 shares of Phathom Pharmaceuticals stock. The shares were sold at an average price of $8.00, for a total value of $8,944.00.

Phathom Pharmaceuticals Stock Down 3.8 %

NASDAQ:PHAT opened at $6.90 on Friday. The business’s 50-day moving average price is $8.04 and its two-hundred day moving average price is $12.50. Phathom Pharmaceuticals, Inc. has a twelve month low of $6.07 and a twelve month high of $19.71.

Phathom Pharmaceuticals (NASDAQ:PHAT) last announced its earnings results on Thursday, November 7th. The company reported ($1.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.57) by $0.25. The company had revenue of $16.35 million during the quarter, compared to analysts’ expectations of $12.54 million. During the same period in the prior year, the business earned ($0.76) earnings per share. On average, analysts expect that Phathom Pharmaceuticals, Inc. will post -4.74 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on PHAT shares. Needham & Company LLC reissued a “buy” rating and issued a $28.00 price target on shares of Phathom Pharmaceuticals in a report on Friday, January 10th. HC Wainwright reiterated a “buy” rating and issued a $28.00 target price on shares of Phathom Pharmaceuticals in a research note on Thursday, December 12th.

Institutional Trading of Phathom Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in PHAT. Rhumbline Advisers raised its position in Phathom Pharmaceuticals by 17.1% during the second quarter. Rhumbline Advisers now owns 55,178 shares of the company’s stock valued at $568,000 after purchasing an additional 8,075 shares in the last quarter. Marshall Wace LLP purchased a new position in shares of Phathom Pharmaceuticals during the 2nd quarter valued at about $1,161,000. The Manufacturers Life Insurance Company lifted its position in Phathom Pharmaceuticals by 10.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,941 shares of the company’s stock worth $144,000 after buying an additional 1,339 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Phathom Pharmaceuticals in the third quarter worth approximately $244,000. Finally, Creative Planning grew its position in Phathom Pharmaceuticals by 25.7% during the third quarter. Creative Planning now owns 33,884 shares of the company’s stock valued at $613,000 after acquiring an additional 6,933 shares during the last quarter. Hedge funds and other institutional investors own 99.01% of the company’s stock.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc, biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach.